50963-77-4

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-aminophenoxy)-1-ethanol is used as a chemical intermediate for the production of various pharmaceuticals. Its unique structure allows it to be a key component in the synthesis of drugs, contributing to the development of new medications.
Used in Agrochemical Industry:
APE is utilized as a chemical intermediate in the creation of agrochemicals, playing a crucial role in the formulation of products designed to enhance crop protection and yield.
Used in Dye Industry:
In the dye industry, 2-(3-aminophenoxy)-1-ethanol is employed as an intermediate, facilitating the production of a range of dyes used in different applications, from textiles to printing.
Used as a Corrosion Inhibitor:
APE serves as an effective corrosion inhibitor, protecting materials from the damaging effects of corrosion, which is particularly valuable in industries such as automotive and manufacturing where metal preservation is crucial.
Used in Surfactant Synthesis:
2-(3-aminophenoxy)-1-ethanol is used as an intermediate in the synthesis of surfactants, which are essential in the production of detergents, cleaners, and other products that require the reduction of surface tension.
Used in Specialty Chemicals:
APE is also utilized in the synthesis of other specialty chemicals, highlighting its adaptability and importance in the chemical industry for creating tailored products for specific applications.

InChI:InChI=1/C8H11NO2/c9-7-2-1-3-8(6-7)11-5-4-10/h1-3,6,10H,4-5,9H2

Upstream product

• 16365-26-7 2-(3-nitrophenoxy)ethanol 
• 5544-77-4 2-(3-nitrophenoxy)-acetic acid ethyl ester 
• 554-84-7 meta-nitrophenol 
• 1448309-95-2 N-(4,4-difluorocyclohexyl)formamide 
• 96042-30-7 4-(dicyanomethylene)-2-methyl-6-(p-dimethylaminostyryl)-4H-pyran 
• 58559-52-7 3-aminophenoxyacetic acid ethyl ester 

Downstream Products

• 920946-30-1 1-benzyl-3-[3-(2-hydroxyethoxy)phenylamino]pyrrole-2,5-dione 
• 857578-88-2 [3-(2-hydroxy-ethoxy)-2-nitro-phenyl]-arsonic acid 
• 857578-87-1 [3-(2-hydroxy-ethoxy)-4-nitro-phenyl]-arsonic acid 
• 854228-49-2 2-(5-arsenoso-2-nitro-phenoxy)-ethanol 
• 854228-50-5 2-(3-arsenoso-2-nitro-phenoxy)-ethanol 
• 857628-58-1 (3-hydroxy-2-nitro-phenyl)-arsonic acid 
• 860517-82-4 (3-hydroxy-4-nitro-phenyl)-arsonic acid 
• 860518-06-5 [3-(2-hydroxy-ethoxy)-phenyl]-arsonic acid 

Relevant academic research and scientific papers

Copper nanoparticles (CuNPs) catalyzed chemoselective reduction of nitroarenes in aqueous medium

Abstract: A procedure for practical synthesis of CuNPs from CuSO4·5H2O is established, under appropriate reaction conditions, using rice (Oryza sativa) as an economic source of reducing as well as a stabilizing agent. Optical and microscopic techniques are employed for the characterization of the synthesized CuNPs and the sizes of the particles were found to be in the range of 8 ± 2 nm. The nanoparticles are used as a catalyst for chemoselective reduction of aromatic nitro compounds to corresponding amines under ambient conditions and water as a reaction medium. Graphic abstract: CuNPs are synthesized using hydrolysed rice and used as catalyst for chemoselective reduction of nitroarenes to their corresponding amines in water. [Figure not available: see fulltext.]

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND USE THEREOF

Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.

Deacetylcolchicine deriv.

Provided are 4-modified colchicine compounds and medicines using the same. Specifically provided are colchicine derivatives represented by general formula (1), salts thereof, and solvates of the same. In general formula (1), R1 is a halogen atom, a hydroxyl group, a nitro group, an amino group, or a mono-, di- or tri-fluoromethyl group; R2, R3 and R4 are each a methoxy group or a hydroxyl group, or alternatively R2 and R3, or R3 and R4 together represent a methylenedioxy group; R5 and R6 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, an arylalkyl group, a C2-6 alkenyl group, -COR7, -COOR8, -SO2R9, -CONR10R11, or -CSNR12R13, or alternatively R5 and R6 together with the nitrogen atom to which R5 and R6 are bonded may form a three- to seven-membered cyclic amino group; R7 is a C1-6 alkyl group or the like; R8 is a C1-6 alkyl group or the like; R9 is a C1-6 alkyl group or the like; R10 and R11 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, or the like; and R12 and R13 may be the same or different and are each a hydrogen atom, an alkyl group, or the like.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides inhibitors of protein kinases of formula I-a and I-b, pharmaceutically acceptable compositions thereof, and methods of using the same.

2-Aminopyrrole-2,5-diones 2.* vinyl nucleophilic substitution of the alkylamino group in 1-alkyl-3-alkylaminopyrrole-2,5-diones by arylamines

In vinyl nucleophilic substitution (SNvin) with the hydrochlorides or 4-toluenesulfonates of primary arylamines 1-alkyl-3- alkylaminopyrrole-2,5-diones form the corresponding 1-alkyl-3-arylamino-pyrrole- 2,5-diones, which are also produced in s

ENZYME INHIBITORS

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1 , Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, AIk1 and AIk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-O-), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-, -NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4-wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; z is 0 or 1 ; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R1R2NH-Y-L1-X1-[CH2]Z- and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.